Aurora Cannabis (TSX:ACB) vs. Canada Goose Holdings (TSX:GOOS): Earnings Guidance Misses Make 1 Stock a Buy

Management can miss own earnings guidance by a wide margin. Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) did so recently, but a similar flaw makes Canada Goose Holdings Inc. (TSX:GOOS)(NYSE:GOOS) stock a great buy today.

| More on:

Premium apparel manufacturer Canada Goose Holdings (TSX:GOOS)(NYSE:GOOS) stock price fell 16% within days after an earnings release in August when management didn’t update its revenue guidance for fiscal 2020, even after reporting staggering first-quarter growth numbers.

On a similar note relating to management earnings guidance, cannabis growth stock Aurora Cannabis (TSX:ACB)(NYSE:ACB) tanked significantly in September after management surprisingly missed its own revenue guidance, which it had “safely” issued a good 36 days after quarter close. This was a punishable offence on the market.

Aurora also missed its earlier guidance for positive adjusted EBITDA for the quarter ended in June this year.

Significance of revenue guidance

Executives are key corporate insiders who are known to possess material insider information pertaining to corporate financial performance, and investors have to take any earnings guidance’s from these elite and privileged teams very seriously.

But management can make too aggressive or too conservative earnings forecasts and give revenue guidance that can be wide off the mark, more so if the company has just entered new markets or launched new products.

The two companies are both high-growth companies, which have recently ventured into new geographical and/or product markets in their respective marijuana and premium apparel trades, and management teams are yet to fully understand the new markets and refine their forecasting precision.

That said, although Aurora is still a youthful market leader, I still wonder how executives could miss quarterly revenue by over 4% when the guidance was given after quarter close. Probably internal auditors disallowed revenue recognition on some sales that were yet to fully comply with recognition principles and deferred the revenue to the next quarter. Adjusted EBITDA is more complex to forecast than revenue.

If Aurora management could miss revenue guidance from a point of knowledge, how much more precise can a busy Canada Goose executive team be after unexpected demand surges in Asia and Europe and surprise growth from traditional markets during the past quarter?

GOOS’s guidance could miss by a wide mark, and that’s great!

Canada Goose has made forays into direct retail markets and announced new product launches recently, and its seemingly conservative management could easily underestimate the business’s growth potential, just like it did last year.

The company reported a staggering 59% year-over-year revenue growth for the first quarter of fiscal 2020 as direct-to-customer (DTC) sales increased by 50% and wholesale revenue surged nearly 69% year over year.

But management chose to maintain their earlier annual revenue growth guidance (given in May 2019) of at least 20% for fiscal 2020, with wholesale revenue growth expected in the high single digits for the year.

This was alarming, especially considering the just released strong growth rates for the first quarter, which is historically a lousy quarter due to seasonality, but new markets in Europe and the rest of the world still reported nearly 80% growth, with Asia sales tripling.

Management resisted the strong urge to increase its annual sales guidance after a strong start to the year, and the share price tanked as low as 16% within days after earnings, as investors feared significant sales weaknesses in future quarters if annual sales are to fall in line with management guidance.

Whether this is extreme conservatism or poor revenue forecasting, the company is likely to surpass management’s revenue guidance for fiscal 2020 by a very wide margin as it did for fiscal 2019 where total sales grew 40% and wholesale revenue grew 18.7% year over year against a guidance for a 20% and “mid-single-digit” growth, respectively.

This makes the stock a great buy with significant recovery prospects back to all-time highs, as subsequent quarterly results beat management estimates thoroughly in the next three quarterly reports.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »